SAN DIEGO, June 7, 2016 /PRNewswire/ -- Sequenom, Inc.,
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that it filed a patent infringement
lawsuit in Australia. The patent
relates to the detection of cell-free fetal DNA for non-invasive
prenatal testing (NIPT).
The lawsuit was filed against Sonic Healthcare, Australian
Clinical Labs and Ariosa Diagnostics, Inc. in the Australian
Federal Court. The suit accuses Sonic Healthcare and Australian
Clinical Labs' use of the Harmony™ NIPT test supplied by Ariosa of
infringing Australian Patent 727,919. Sequenom is seeking all
available remedies, including damages (or an account of profits)
and orders of restraint.
"Sequenom established the NIPT market with the introduction of
the MaterniT® 21 laboratory-developed test in 2011 and has
developed pioneering intellectual property in the NIPT testing
field," said Dirk van den Boom,
Ph.D., President and CEO of Sequenom. "In 2014 we entered
into an agreement with Illumina, Inc. to pool our NIPT intellectual
property and allow for easier access to both parties' NIPT
technology by healthcare providers and their patients.
Currently, over 45 healthcare organizations globally have
licensed the intellectual property in order to develop and deliver
the highest quality NIPT tests. We are committed to
preserving the value of the intellectual property of the patent
pool for the benefit of our licensees, and this lawsuit adds to
suits already filed in the U.K. and in Europe."
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is
committed to enabling healthier lives through the development of
innovative products and services. The Company serves patients and
physicians by providing early patient management information.
To learn how Sequenom is interpreting the genome to improve your
life, visit www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a
CAP-accredited and CLIA-certified molecular diagnostics laboratory,
has developed a broad range of laboratory tests, with a focus
principally on prenatal care. Branded under the names HerediT®,
HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT® 21 PLUS, NextView®,
SensiGene® and VisibiliT™, these molecular genetic
laboratory-developed tests provide early patient management
information for obstetricians, geneticists, and maternal fetal
medicine specialists. Sequenom Laboratories is changing the
landscape in genetic diagnostics using proprietary cutting edge
technologies. Visit www.laboratories.sequenom.com and follow
@SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT®, NextView®, SensiGene®,
VisibiliT™ and Sequenom Laboratories™ are
trademarks of Sequenom, Inc. All other trademarks and service marks
are the property of their respective owners.
Logo - http://photos.prnewswire.com/prnh/20160225/337675LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-files-patent-infringement-lawsuit-in-australia-300280671.html
SOURCE Sequenom, Inc.